title: Raloxifene inhibits hepatitis C virus infection and replication.
abstract: Postmenopausal women with chronic hepatitis C exhibited a poor response to interferon (IFN) therapy compared to premenopausal women. Osteoporosis is the typical complication that occurs in postmenopausal women. Recently, it was reported that an osteoporotic reagent, vitamin D3, exhibited anti-hepatitis C virus (HCV) activity. Therefore, we investigated whether or not another osteoporotic reagent, raloxifene, would exhibit anti-HCV activity in cell culture systems. Here, we demonstrated that raloxifene inhibited HCV RNA replication in genotype 1b and infection in genotype 2a. Raloxifene enhanced the anti-HCV activity of IFN-α. These results suggest a link between the molecular biology of osteoporosis and the HCV life cycle.
authors: Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.
authors: Midori
authors: M
authors: Takeda
authors: Masanori
authors: M
authors: Ikeda
authors: Kyoko
authors: K
authors: Mori
authors: Masahiko
authors: M
authors: Yano
authors: Yasuo
authors: Y
authors: Ariumi
authors: Hiromichi
authors: H
authors: Dansako
authors: Takaji
authors: T
authors: Wakita
authors: Nobuyuki
authors: N
authors: Kato
keywords: Estrogen; Hepatitis C virus; Osteoporosis; Raloxifene; Statin
references: J Gen Virol. 2012 Jul;93(Pt 7):1422-1431
references: 22456614
references: J Virol. 1996 May;70(5):3307-12
references: 8627816
references: Intervirology. 2009;52(1):43-8
references: 19372703
references: Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-5
references: 21872200
references: Gastroenterology. 2011 Jan;140(1):144-52
references: 20833169
references: Proc Natl Acad Sci U S A. 1990 Dec;87(24):9524-8
references: 2175903
references: Nat Med. 2005 Jul;11(7):791-6
references: 15951748
references: Acta Med Okayama. 2001 Jun;55(3):133-59
references: 11434427
references: Microbiol Immunol. 2010 Nov;54(11):684-90
references: 21044142
references: Am J Gastroenterol. 2008 Jun;103(6):1383-9
references: 18410471
references: Biochem Biophys Res Commun. 2003 Jul 4;306(3):756-66
references: 12810084
references: Hepatology. 2011 Aug;54(2):748
references: 21384407
references: J Pharmacol Sci. 2007 Oct;105(2):145-50
references: 17928739
references: Arch Intern Med. 1998 Jan 26;158(2):177-81
references: 9448556
references: Biochem Biophys Res Commun. 2005 Apr 22;329(4):1350-9
references: 15766575
references: Science. 1999 Jul 2;285(5424):110-3
references: 10390360
references: Hepatology. 2012 Oct;56(4):1231-9
references: 22487892
references: N Engl J Med. 2009 Apr 30;360(18):1827-38
references: 19403902
references: J Biol Chem. 2007 Nov 9;282(45):32765-72
references: 17704057
references: World J Gastroenterol. 2011 Dec 21;17(47):5184-90
references: 22215943
references: Hepatology. 2006 Jul;44(1):117-25
references: 16799963
references: J Virol. 2002 Mar;76(6):2997-3006
references: 11861865
references: Hepatology. 2006 Jan;43(1):54-63
references: 16374855
references: Hepatology. 2011 Nov;54(5):1570-9
references: 21793032
references: Cancer Res. 1982 Sep;42(9):3858-63
references: 6286115
references: J Virol. 2002 Apr;76(8):4008-21
references: 11907240
references: Transpl Int. 2011 Jan;24(1):43-50
references: 20649944
references: Science. 2005 Mar 11;307(5715):1625-30
references: 15705806